FDA Pumps Brakes On Eli Lilly Alzheimer's Drug Approval
By Yeji Jesse Lee · March 8, 2024, 9:21 PM EST
The U.S. Food and Drug Administration is delaying an approval decision on Eli Lilly and Co.'s Alzheimer's drug donanemab, the company said Friday, throwing a wrench in what was expected to...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login